Analysis of PD-L1, TMB, MSI and Circulating Tumor DNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• 18 years and older, both genders.
• Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.
• FFPE/FNA sample is available.
• Compliant with treatment protocol.
• Patients consented to participate in the study.
Locations
Other Locations
Viet Nam
Medical Genetics Institute
NOT_YET_RECRUITING
Ho Chi Minh City
University of Medicine and Pharmacy at HCMC
RECRUITING
Ho Chi Minh City
Contact Information
Primary
Lan NL Tu, PHD
lantu@genesolutions.vn
+84888843489
Backup
VAN T Phan, MSc
vanphan@genesolutions.vn
+84908145990
Time Frame
Start Date: 2024-03-22
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: Gene Solutions